Abstract
Hepatocellular carcinoma (HCC) constitutes a major global health burden, with limited responsiveness to current immunotherapeutic regimens. Accumulating evidence underscores the gut microbiota as a crucial regulator of the gut–liver axis, modulating tumor initiation, immune evasion, and the outcomes of immunotherapeutic interventions—and notably, it concurrently exhibits both potential diagnostic biomarker value and actionable therapeutic target properties. In the present review, we synthesize the characteristic features of gut dysbiosis in HCC, delineate the mechanisms by which microbial metabolites—including short-chain fatty acids (SCFAs), bile acids, and indoles—modulate the tumor immune microenvironment (TME), and elaborate on their dual roles in promoting anti-tumor immunity while concomitantly mediating immune suppression. We further examine the clinical correlations between specific microbial taxa and the efficacy of immune checkpoint inhibitors (ICIs)—findings that support the utility of gut microbiota signatures as predictive or diagnostic biomarkers—and explore emerging microbiota-targeted strategies, such as fecal microbiota transplantation (FMT), probiotic supplementation, phage therapy, and dietary modulation, which validate the gut microbiota as a viable therapeutic target.
1 Introduction
HCC, the predominant subtype of primary liver cancer (accounting for 75%–85% of all cases), ranks as the sixth most prevalent malignancy and the third leading cause of cancer-related mortality worldwide. Given its high incidence and mortality, HCC imposes a substantial public health burden globally (). The initiation and progression of HCC are driven by intricate interactions across multiple factors, encompassing persistent inflammatory injury, hepatic fibrosis, dysregulation of oncogenes and tumor suppressor genes (, ), perturbations in the immune microenvironment (, ), metabolic reprogramming (), and the accumulation of genetic and epigenetic alterations. Collectively, these processes contribute to the marked molecular heterogeneity and clinical complexity that characterize HCC ().
Currently, receptor tyrosine kinase inhibitors such as sorafenib and lenvatinib remain the standard first-line therapeutic options for advanced HCC (). More recently, the combination of the anti–PD-L1 antibody atezolizumab and the anti–VEGF antibody bevacizumab has demonstrated significant superiority over sorafenib in terms of overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) (, ). The HIMALAYA trial further revealed that dual immunotherapy with durvalumab (an anti–PD-L1 agent) and tremelimumab (an anti–CTLA-4 agent) achieved a 4-year OS rate of 25.2%, thereby expanding the available treatment armamentarium for HCC (). Nevertheless, the prognosis of HCC remains dismal: only approximately 30% of patients achieve objective responses to current therapies, the 3-year OS rate remains below 50% (), and response rates to monotherapy with ICIs are as low as 15%–20% (13). The challenges of immunotherapy resistance, low response rates, limited predictive biomarkers, and insufficient understanding of the relationship between the TME and treatment efficacy underscore the urgent need to dissect the immune regulatory networks governing HCC.
In recent years, a growing body of evidence has identified the gut microbiota—a central regulator of the “gut–liver axis—as a key mediator of HCC pathogenesis. Beyond contributing to tumor initiation and progression via microbial metabolites, the gut microbiota also modulates therapeutic responses through immune regulation. However, the cascade mechanisms linking the microbiota, its metabolites, and immunotherapeutic responses have not been systematically integrated. To address this knowledge gap, the present review provides the first comprehensive synthesis of the “microbiota–metabolite–immunotherapy” cascade in HCC. We systematically examine the molecular mechanisms through which the gut microbiota regulates immune homeostasis via the gut–liver axis, analyze its roles in facilitating immune evasion and shaping responsiveness to immunotherapy, and discuss strategies for microbiota-targeted modulation to optimize HCC immunotherapy. Our overarching aim is to establish a theoretical framework that can overcome current clinical bottlenecks in HCC treatment.
2 Physiological basis and pathological associations of the gut microbiota and gut-liver axis
2.1 Physiological characteristics of the gut microbiota and functional framework of the gut-liver axis
The human gastrointestinal tract harbors approximately 100 trillion microorganisms, forming a highly complex microecosystem. Among these microbes, Firmicutes and Bacteroidetes are the dominant phyla (collectively accounting for >90% of the total microbial community), supplemented by other phyla such as Actinobacteria and Proteobacteria (14). These microorganisms establish symbiotic relationships with the host through metabolic cooperation, immune education, and maintenance of intestinal barrier integrity, thereby regulating nutrient absorption, metabolic balance, and mucosal immune homeostasis (Figure 1).
FIGURE 1
The gut-liver axis functions as a bidirectional communication system that links the intestine and the liver, relying on three core mechanisms: (1) The portal venous system, which drains approximately 70% of intestinal blood, enabling microbial products and metabolites to reach the liver directly (15, 16); (2) Bile acids secreted by the liver, which enter the intestine via the biliary tract, undergo microbial metabolism, and subsequently re-enter the liver to regulate bile acid homeostasis (17); (3) Neuro-immune signaling mediated by the vagus nerve, lymphatic vessels, and cytokines (18). Under physiological conditions, the intestinal barrier (comprising tight junctions and mucosal lymphocytes) and hepatic immune defenses (including Kupffer cells and liver sinusoidal endothelial cells) synergistically prevent microbial translocation, thereby maintaining the homeostasis of the gut-liver axis (19). Once this balance is disrupted—for instance, by dysbiosis or increased intestinal permeability—pathological cascades are triggered, driving the initiation and progression of HCC (20, 21).
2.2 Characteristics of gut microbiota dysbiosis in HCC patients
In HCC, the balance of the gut microbiota and the functionality of the gut-liver axis are profoundly disrupted, leading to distinct patterns of dysbiosis. β-diversity analysis reveals a significant separation between the microbial communities of HCC patients and healthy individuals (R2 = 0.152, P = 0.001), indicating a systemic remodeling of the microbial community structure (22). This shift not only involves changes in the abundance of specific taxa but also reflects disruptions in microbial interaction networks—including the breakdown of cooperative relationships between dominant and commensal bacteria—thereby impairing the regulatory capacity of the gut-liver axis.
At the phylum level, HCC patients typically exhibit increased abundance of the pro-inflammatory phylum Proteobacteria, whereas the relative abundances of Firmicutes, Verrucomicrobia, and certain subtypes of Actinobacteria are significantly reduced (23, 24). Dysbiosis patterns also vary according to disease stage and etiology: patients with advanced HCC display enrichment of Proteobacteria and Patescibacteria, accompanied by progressive loss of Actinobacteria (23); patients with HBV-related HCC show reduced levels of Proteobacteria, while those with HCV-related HCC (derived from HCV-associated cirrhosis) exhibit elevated Proteobacteria abundance, suggesting that etiological factors shape microbial dysbiosis patterns during cirrhosis-to-HCC progression and thereby influence HCC development through distinct microbial pathways (25).
At the genus level, dysbiosis exhibits greater specificity: pathogenic genera such as Escherichia/Shigella, Enterobacter, Klebsiella, and Haemophilus are significantly enriched, whereas probiotic genera with immunomodulatory or metabolic protective roles—including Lactobacillus, Bifidobacterium, Bacteroides, and the Lachnospiraceae NK4A136 group—are depleted (26, 27). Even in early-stage HCC, clear differences in microbial composition are observed: 13 genera (including Gemmiger and Parabacteroides) are increased, while 12 genera (including Alistipes and Phascolarctobacterium) are decreased (24). Critically, bacteria that produce pro-inflammatory lipopolysaccharide (LPS) are enriched, whereas those that generate anti-inflammatory metabolites (e.g., butyrate) are reduced, directly fostering a local pro-carcinogenic microenvironment within the liver (28).
2.3 Core mechanisms by which the gut microbiota regulates HCC through the gut-liver axis
The central mechanism by which dysbiosis promotes HCC via the gut-liver axis can be summarized as a cascade of “barrier disruption → microbial translocation → hepatic pathological remodeling.” This cascade involves intestinal barrier damage, chronic inflammation, metabolic imbalance, immune suppression, and epigenetic interactions between the host and microbiota:
Intestinal barrier damage serves as the initiating step. Factors such as a high-fat diet, alcohol consumption, and viral infection can disrupt intestinal tight junctions (e.g., by decreasing the expression of Occludin and Claudin), thereby increasing intestinal permeability (29, 30). Dysbiosis—for example, the expansion of Proteobacteria—further exacerbates barrier injury by producing metabolites such as LPS, enabling microbial products (including LPS and lipoteichoic acid) to translocate to the liver via the portal vein (28, 31). These ectopic microbial signals continuously stimulate hepatic innate immune cells, initiating the developmental cascade of HCC.
Chronic inflammation arises from the recognition of microbial components by hepatic immune cells. LPS activates the TLR4/NF-κB pathway, upregulating the expression of proto-oncogenes such as C-Myc and Cyclin D1 to induce DNA damage and mutations in hepatocytes; lipoteichoic acid activates toll-like receptors (TLRs) in hepatic stellate cells, promoting the secretion of IL-6 and IL-17 and accelerating tumor cell proliferation via the STAT3/Cyclin E signaling axis (32); the enrichment of pro-inflammatory Enterobacteriaceae strengthens the hepatic pro-inflammatory milieu, facilitating the transformation of cirrhosis to HCC (33).
Metabolite dysregulation reshapes hepatic pathology. Reduced SCFA levels impair intestinal barrier integrity and weaken anti-inflammatory signaling (26, 34, 35). Secondary bile acids (e.g., DCA) disrupt lipid metabolism via FXR/TGR5 signaling, while dysbiosis (e.g., the overgrowth of E. coli) causes abnormal bile acid profiles, promoting hepatic steatosis and carcinogenesis (17). Additionally, LPS promotes angiogenesis and tumor cell proliferation by activating inflammatory pathways (28).
Epigenetic regulation links microbial metabolites to the expression of host genes. Butyrate enhances the transcription of the tumor suppressor gene TP53 by inhibiting histone deacetylase (HDAC) activity (34), whereas DCA activates β-catenin (encoded by CTNNB1), promoting the expression of oncogenes (17). Immune suppression is further reinforced by dysbiosis: pathogenic metabolites (e.g., those derived from Klebsiella) inhibit the infiltration and activity of CD8+ T cells while expanding Treg populations, creating an immunosuppressive TME (36). Intratumoral microbiota such as Ruminococcus further accelerate HCC progression by inducing the release of TNF-α (37).
3 Interaction mechanisms between the gut microbiota and the HCC immune microenvironment
The TME of HCC is characterized by profound immunosuppression, marked by the infiltration of large numbers of suppressive immune cells (e.g., tumor-associated macrophages [TAMs], regulatory T cells [Tregs]) and the presence of inhibitory signaling molecules. Together, these elements form an immunosuppressive barrier that facilitates tumor immune evasion (38). Through the gut-liver axis, the gut microbiota regulates the differentiation and function of diverse immune cell populations within the TME, establishing a complex “microbiota–immunity–tumor” interaction network (Figure 2).
FIGURE 2
3.1 Targeted regulation of HCC immune cells by the gut microbiota
3.1.1 Functional regulation of T Cells and natural killer (NK) cells
CD8+ cytotoxic T cells, the central effector cells of anti-tumor immunity, are profoundly influenced by the gut microbiota, which modulates their activity and functional status to directly affect tumor clearance. For example, acetate secreted by Bacteroides thetaiotaomicron enhances the cytotoxicity of CD8+ T cells and their secretion of IFN-γ, thereby promoting the killing of tumor cells (39). Similarly, 2,5-dimethylcelecoxib enriches the abundance of Acidaminococcus and reduces PD-1 expression in CD8+ T cells via the AMPK/mTOR pathway, effectively reversing T cell exhaustion and restoring anti-tumor function (40).
For CD4+ T cell subsets, the microbiota influences immune balance by regulating their differentiation. Limosilactobacillus reuteri activates Th1 immune responses via its metabolite indole-3-aldehyde, thereby promoting anti-tumor immunity, while concurrently inhibiting Th2-mediated pro-tumor inflammation (41).
Innate immunity is likewise regulated by the gut microbiota: Bacteroides uniformis and Bifidobacterium bifidum restore the cytotoxicity of NK cells by enhancing the expression of granzyme B (42), while Lactobacillus plantarum increases the secretion of IL-22 in NK cells, augmenting tumor cell clearance and complementing adaptive immune responses (43).
3.1.2 Regulation of macrophage polarization balance
Macrophage polarization is a key determinant of the TME phenotype. M1 macrophages exert anti-tumor effects through the secretion of TNF-α and IL-1β, whereas M2 macrophages promote angiogenesis and release suppressive cytokines, thereby accelerating tumor progression (44–46). The gut microbiota can direct macrophage polarization via its metabolites: D-lactic acid produced by Lactobacillus delbrueckii promotes the repolarization of M2 macrophages to an M1 phenotype via the TLR2/TLR9–PI3K/Akt pathway, enhancing anti-tumor immunity (13); conversely, SCFAs may recruit M2 macrophages through GPR43 signaling, promoting the formation of an immunosuppressive TME (47). This bidirectional regulation highlights the fine-tuning capacity of the gut microbiota in shaping macrophage function and the immune phenotype of the TME.
3.1.3 Functional remodeling of antigen-presenting cells
Dendritic cells (DCs)—the bridge between innate and adaptive immunity—rely on their maturation status to initiate effective T cell responses, a process that is strongly influenced by the gut microbiota. Bifidobacterium spp. enhance the antigen-presenting capacity of DCs by upregulating the expression of CD80/CD86, thereby driving the infiltration of CD8+ T cells into tumors (13). Similarly, the probiotic Escherichia coli Nissle 1917 induces DCs to secrete IL-12, amplifying Th1 immune responses and providing priming signals for adaptive immunity (48). Thus, the modulation of DC function represents a pivotal node linking gut ecology to systemic anti-tumor immunity. Specifically, microbiota-activated mature DCs not only prime CD8+ T cell differentiation into cytotoxic T lymphocytes via IL-12 secretion but also secrete TNF-α to promote M1 macrophage polarization, forming a synergistic anti-tumor immune loop (13, 48).
3.1.4 Abnormal activation of immunosuppressive cells
Myeloid-derived suppressor cells (MDSCs) and Tregs—major immunosuppressive cell types within the TME—play central roles in HCC immune evasion, and their activation is strongly influenced by the gut microbiota. Dysbiosis promotes the hepatic recruitment of MDSCs via the TLR4/NF-κB pathway, establishing a vicious “inflammation–immunosuppression” cycle with IL-6 and IL-1β that progressively diminishes anti-tumor immunity (49–51). The SCFA butyrate strengthens Treg function via histone acetylation at the Foxp3 locus (52, 53), while outer membrane vesicles derived from Bacteroides fragilis induce Tregs to secrete IL-10, consolidating the immunosuppressive microenvironment (54, 55).
3.2 Integrated effects of the inflammation–immunity synergistic network
The interaction between inflammation and immunity constitutes the core mechanism by which the gut microbiota modulates the HCC TME. This interaction is manifested in the crosstalk of signaling pathways, the regulation of metabolic networks, and the metabolic reprogramming of immune cells.
On one hand, microbial components such as LPS and peptidoglycan activate downstream signaling pathways through TLRs. For example, the LPS–TLR4 axis stimulates Kupffer cells to produce TNF-α and IL-6, while simultaneously inducing the expression of PD-L1, which suppresses T cell function (56, 57). Conversely, the activation of TLR5 promotes DC maturation via MyD88, partially counteracting immunosuppression (58). This dual regulation underscores the complexity of microbiota–immune interactions in the context of HCC.
On the other hand, gut microbes influence immune metabolism. Akkermansia muciniphila exemplifies a bacterium with dual regulatory effects: it reduces liver inflammation by repairing the intestinal barrier (thereby decreasing LPS translocation) while simultaneously enhancing anti-tumor immunity through IL-12–dependent crosstalk between DCs and T cells (59).
Microbial metabolites also remodel the metabolism of immune cells. Acetate derived from Bacteroides thetaiotaomicron reverses the Warburg effect in CD8+ T cells by inhibiting glycolytic enzymes (e.g., hexokinase), enhancing mitochondrial oxidative phosphorylation and T cell cytotoxicity (39). In contrast, lactic acid produced by Enterococcus activates the mTOR–HIF1α pathway in Tregs, reinforcing their glucose-dependent metabolism and immunosuppressive function (55). Additionally, microbial metabolites can activate the cyclic GMP–AMP synthase (cGAS)/stimulator of interferon genes (STING) pathway, which in turn reshapes type I interferon signaling within the TME (48).
4 Mechanisms by which the gut microbiota influences HCC through regulation of immune evasion
Immune evasion is a defining hallmark of HCC, whereby tumor cells reshape the TME and alter their own phenotypes to escape immune surveillance. This process is a key driver of malignant progression and therapeutic resistance. Given the extensive regulatory effects of the gut microbiota on the HCC immune microenvironment, the gut microbiota—via the gut-liver axis—further contributes to immune evasion through multiple pathways, thereby serving as a critical bridge between intestinal dysbiosis and hepatic immune dysfunction (60–62).
4.1 Core mechanisms of HCC immune evasion: synergistic effects of the microenvironment and tumor cells
Immune evasion in HCC is a multi-faceted process driven by the dynamic interaction between the TME and tumor cells themselves. To understand how the gut microbiota regulates this process, it is first necessary to clarify the core endogenous mechanisms of HCC immune evasion, which provide the biological context for the subsequent regulatory role of the gut microbiota. Immune evasion in HCC is not mediated by a single factor but arises from dynamic interactions between the TME and the intrinsic properties of tumor cells. Central mechanisms include the formation of an immunosuppressive TME, the role of tumor-initiating cells (TICs), the intrinsic immune-evasion phenotypes of tumor cells, and microbiota-driven immune editing—all of which collectively establish an “immune shelter” for tumor cells.
4.1.1 Construction of an immunosuppressive TME
The intrinsic immune tolerance of the liver provides a baseline permissive environment for tumor immune escape. In HCC, this tolerance is reinforced by a suppressive cellular network within the TME. Kupffer cells, Tregs, and MDSCs form a fundamental suppressive axis: TAMs inhibit the cytotoxicity of CD8+ T cells by secreting IL-10 and TGF-β and by upregulating PD-L1 expression. In parallel, neutrophils release arginase 1, depleting arginine and thereby impairing T cell proliferation (31, 63, 64). These suppressive cells cooperate with extracellular matrix components (e.g., collagen, hyaluronic acid) to establish both physical and functional barriers that block anti-tumor immune responses.
4.1.2 Immune evasion driven by tumor-initiating cells
On the basis of the immunosuppressive TME, tumor-initiating cells (TICs)—a subpopulation of tumor cells with potent tumorigenic and drug-resistant properties—act as key engines of immune evasion, further exacerbating the escape of tumor cells from immune surveillance (65, 66). CD49f+ TICs recruit pro-tumor neutrophils via the CXCL2–CXCR2 axis, forming a positive feedback loop in which neutrophil-derived CCL4 reprograms surrounding tumor cells into a TIC phenotype (67, 68). TICs further evade recognition and killing by CD8+ T cells by upregulating the expression of CD155 (69, 70). Additionally, activation of the WNT–β-catenin pathway reduces the expression of antigen presentation molecules, lowering the immunogenicity of TICs and facilitating immune escape.
4.1.3 Intrinsic immune evasion characteristics of tumor cells
Beyond the influence of the TME and TICs, genetic and epigenetic alterations in tumor cells themselves confer inherent immune-evasive traits, which are an important intrinsic factor in HCC immune evasion. Mutations in TP53 diminish the sensitivity of tumor cells to cytotoxic T cells by inhibiting IFN-γ signaling, while activation of β-catenin suppresses the secretion of CXCL10, reducing the infiltration of T cells into the TME (71). Moreover, tumor cells upregulate the expression of checkpoint molecules such as PD-L1 and B7-H3, which function as molecular shields to block T cell recognition and activation, thereby establishing autonomous immune evasion mechanisms (72, 73).
4.1.4 Role of microbiota in immune editing
The gut microbiota is not only a regulator of the above endogenous immune evasion mechanisms but also participates in the immune editing process of tumors, shaping the clonal evolution of HCC cells and thereby influencing their immune evasion potential. The gut microbiota contributes to immune editing by shaping the clonal evolution of tumors. Initially, microbial metabolites (e.g., LPS) enhance immune surveillance via the activation of TLR4, eliminating highly immunogenic tumor clones. However, prolonged dysbiosis—for example, the depletion of butyrate-producing bacteria—weakens immune clearance by reducing anti-tumor cytokine secretion (e.g., IFN-γ), allowing poorly immunogenic clones to dominate (36). For instance, the enrichment of Klebsiella pneumoniae can induce epigenetic silencing of HLA-A in tumor cells, reducing their recognition by CD8+ T cells and enabling these clones to prevail after immune selection (36).
4.2 Key pathways by which the gut microbiota regulates HCC immune evasion
Having clarified the core endogenous mechanisms of HCC immune evasion, it is evident that the gut microbiota intervenes in this process through multiple key pathways via the gut-liver axis. These pathways connect intestinal dysbiosis to hepatic immune dysfunction, directly driving the immune evasion of HCC cells.
4.2.1 Intestinal barrier damage and activation of immunosuppressive signals
The integrity of the intestinal barrier is the first line of defense against microbial translocation, and its damage is the initial step by which the gut microbiota initiates the regulation of HCC immune evasion. The integrity of the intestinal barrier relies on the synergy between the microbiota and mucosal immunity. Dysbiosis—particularly the expansion of Proteobacteria—disrupts the expression of tight junction proteins (e.g., Occludin, ZO-1), increasing intestinal permeability (69, 70),a phenomenon also observed in cirrhotic portal hypertension (CPH, a key HCC precursor) where gut microbiota dysbiosis similarly impairs intestinal barrier function (74). Consequently, microbial products such as LPS and peptidoglycan translocate to the liver via the portal vein. Chronic stimulation of hepatic immune cells and tumor cells via TLRs induces “LPS tolerance,” which involves the activation of the SMAD/STAT3 pathway and the secretion of factors such as TGF-β and hepatocyte growth factor (HGF). These factors inhibit DC maturation and T cell activity, thereby fostering an immunosuppressive TME (75, 76).
4.2.2 Differentiation and functional enhancement of immunosuppressive cells
Intestinal barrier damage and the subsequent activation of immunosuppressive signals further drive the differentiation and functional enhancement of immunosuppressive cells in the liver, which is another key pathway by which the gut microbiota promotes HCC immune evasion, forming a “barrier damage–signal activation–suppressive cell expansion” cascade. Gut microbes promote the expansion and activation of suppressive cell populations, reinforcing immune evasion. Certain pathogenic bacteria (e.g., Enterococcus) induce the recruitment of IL-10+ Tregs in the liver, thereby suppressing the clonal expansion of CD8+ T cells (77). Secondary bile acids such as isoalloLCA enhance the expression of FOXP3 via mitochondrial ROS signaling, while isoDCA indirectly augments Treg function through the activation of vitamin D receptor (VDR) in DCs (75, 78).
Similarly, gut dysbiosis drives the accumulation of MDSCs in the liver via TLR4/NF-κB signaling (79). MDSCs suppress T cell proliferation by producing reactive oxygen species (ROS) and inducible nitric oxide synthase (iNOS) and establish a feedback loop with IL-6 that perpetuates inflammation and immunosuppression (49–51). Studies have shown that IL-6 exerts its effects in the liver through its pro-inflammatory functions, promoting liver fibrosis, steatosis, and carcinogenesis, indicating that IL-6 is one of the key drivers of hepatocellular carcinoma development (80). High serum IL-6 levels are a key indicator of inflammatory dysregulation, and a state of persistent elevation is directly associated with an increased risk of hepatocellular carcinoma progression (81). This mechanism synergizes with TIC-mediated neutrophil recruitment, collectively destabilizing immune homeostasis in the liver.
4.2.3 Regulation of immune checkpoints and tumor cell phenotypes
In addition to regulating the intestinal barrier and immunosuppressive cells, the gut microbiota and its metabolites also directly modulate the expression of immune checkpoints and the phenotypic characteristics of tumor cells, which is a more direct pathway to promote HCC immune evasion, linking microbial regulation to the intrinsic immune evasion traits of tumor cells. The gut microbiota and its metabolites enhance tumor immune evasion by regulating the expression of immune checkpoints and modifying tumor cell phenotypes. Dysbiosis activates the EGFR/RAS pathway, driving the overexpression of PD-L1 on tumor cells (82, 83). Meanwhile, reduced SCFA levels—resulting from the depletion of butyrate-producing bacteria—diminish the epigenetic repression of PD-L1 (via reduced HDAC inhibition), further elevating PD-L1 expression (84). Similarly, microbial metabolites such as LPS stabilize the expression of CD155 in TICs via the activation of STAT3, maintaining the resistance of TICs to killing by CD8+ T cells (36).
4.3 Dual roles of microbiota metabolites in immune evasion
The above pathways by which the gut microbiota regulates HCC immune evasion are largely mediated by its metabolites, which are the key molecular messengers of the gut-liver axis. Notably, these microbial metabolites do not have a unidirectional regulatory effect on immune evasion but instead exhibit dual roles, with their balance determining the ultimate trend of tumor immune escape. Microbial metabolites function as bidirectional regulators of immune evasion: LPS chronically activates TLR4/NF-κB signaling, inducing the secretion of VEGF and IL-8 to promote angiogenesis and recruit suppressive cells (24). Secondary bile acids such as deoxycholic acid (DCA) drive the polarization of M2 macrophages, reinforcing immunosuppression through the secretion of IL-10 (85, 86); in contrast, butyrate enhances the antigen presentation capacity of tumor cells (e.g., by upregulating MHC-I expression) via HDAC inhibition (87). Isobutyric acid, produced by Bifidobacterium, induces the secretion of IFN-γ by CD8+ T cells, thereby reversing T cell exhaustion (88). Thus, the balance between pro-evasion and anti-evasion metabolites—tightly regulated by the composition of the gut microbiota—critically determines the extent of immune escape in HCC.
5 Mechanisms by which the gut microbiota regulates HCC through influencing immunotherapy response
The introduction of ICIs has transformed the treatment landscape for advanced HCC. However, limited clinical response rates (15%–20% with monotherapy and approximately 30% with combination therapy) and the emergence of therapeutic resistance remain major obstacles (89–92). Given the central role of the gut microbiota in modulating immune evasion, alterations in microbial composition and function are closely associated with immunotherapeutic outcomes, positioning the microbiota as a potential target to enhance therapeutic efficacy.
5.1 Clinical associations between gut microbiota characteristics and HCC immunotherapy response
Clinical studies demonstrate that the diversity of the gut microbiota and the relative abundance of specific genera can serve as predictive biomarkers for the prognosis of immunotherapy. Notably, treatment outcomes are linked not only to the baseline microbial composition but also to dynamic changes in the microbiota during therapy. For example, in patients receiving anti–PD-1 therapy, responders exhibit significant differences in microbial diversity before and after treatment (P = 0.0274), whereas baseline α-diversity does not differ significantly between responders and non-responders (93). β-diversity analyses reveal a clear separation in microbial community structure between responders and non-responders, indicating that systemic shifts in the microbiota may underlie the heterogeneity of therapeutic responses.
Reduced microbial diversity is frequently accompanied by the enrichment of immunosuppressive species (e.g., K. pneumoniae), whereas higher diversity supports a more balanced anti-tumor immune response (31) (Table 1).
TABLE 1
| Name | Type | Modality | Target | Phase |
|---|---|---|---|---|
| EMERALD-1 (NCT03778957) | Clinical trial | Durvalumab + bevacizumab + TACE vs. TACE ± Placebo | PD-L1, VEGF | Phase Ⅲ |
| LEAP-012 (NCT04246177) | Clinical trial | Pembrolizumab + lenvatinib + TACE vs. TACE ± Placebo | PD-1, VEGFRs | Phase Ⅲ |
| SCG101 (NCT06617000) | Cell therapy trial | HBV-specific TCR-T | HBV-related antigens | Phase I |
| AZD-7003 (NCT05155189) | Cell therapy trial | GPC3-targeted CAR-T | GPC3 | Phase I |
| CT011 (NCT02395250) | Cell therapy trial | GPC3-targeted CAR-T | GPC3 | Phase I |
| MG4101 (NCT02008929) | Cell therapy trial | Allogeneic NK cells | Innate immunity | Phase II |
| Domvanalimab | Drug development | Checkpoint inhibitor (TIGIT inhibitor) | TIGIT | Preclinical |
| Anti-TIM3 antibody | Drug development | Checkpoint inhibitor (TIM-3 inhibitor) | TIM-3 | Preclinical |
| GS-0151 | Drug development | Anti-PD-1 antibody | PD-1 | Phase I |
| CD147-ADC | Drug development | ADC | CD147 | Pre-IND |
| Dual-target CAR-T | Cell therapy development | CAR-T (GPC3/AFP dual-targeted) | GPC3/AFP | IND-enabling |
Clinical trials and innovative therapies for HCC.
Several genera exhibit quantitative associations with therapeutic efficacy: the presence of Akkermansia muciniphila correlates with improved survival in patients receiving anti–PD-1 treatment (hazard ratio [HR] = 0.32, 95% confidence interval [CI]: 0.15–0.68) (31); an increased Prevotella/Bacteroidetes ratio and a reduced Firmicutes/Bacteroidetes ratio are associated with higher ORR and prolonged PFS; a high abundance of Lachnospiraceae and a low abundance of Prevotellaceae predict longer PFS, whereas the enrichment of Veillonellaceae predicts a poor prognosis (HR = 2.1, 95% CI: 1.2–3.6) (94, 95). Additionally, Alistipes sp. Marseille-P5997 and Lachnospiraceae bacterium GAM79 are enriched in responders, correlating with extended OS (96).
In addition, several ongoing clinical trials are explicitly investigating the role of gut microbiota in the treatment of hepatocellular carcinoma, such as NCT04729322 (FMT combined with nivolumab in advanced solid tumors), NCT05295962 (reversing drug resistance in unresectable hepatocellular carcinoma through FMT), and NCT05750030 (the FAB-HCC trial, which combines FMT with atezolizumab/bevacizumab for hepatocellular carcinoma with resistance to immunotherapy). These trials aim to verify the effectiveness of microbiota modulation as an adjunct to standard treatments.
5.2 Molecular mechanisms by which the gut microbiota influences HCC immunotherapy response
The gut microbiota influences ICI efficacy through multiple interconnected mechanisms, as elaborated below. First, in terms of immune cell recruitment and activation, Akkermansia muciniphila secretes metabolites that recruit CCR9+CXCR3+CD4+ T cells into the TME via IL-12–dependent mechanisms, while simultaneously increasing the infiltration of CD8+ T cells and the apoptosis of tumor cells (55); similarly, Limosilactobacillus reuteri colonizes tumors and produces indole-3-aldehyde (I3A), which activates the aryl hydrocarbon receptor (AhR) pathway in CD8+ T cells to promote the secretion of IFN-γ and enhance responses to ICIs (97), and Bifidobacterium enhances DC maturation by upregulating the expression of CD80/CD86, thereby stimulating the activation of CD8+ T cells and restoring the efficacy of PD-L1 inhibitors (13).
Second, metabolite-driven synergy plays a pivotal role: acetate promotes the polarization of M1 macrophages through ACC1-dependent fatty acid synthesis, indirectly enhancing the activity of CD8+ T cells (98); butyrate boosts the cytotoxicity and memory phenotypes of CD8+ T cells via epigenetic regulation (e.g., histone modification), thereby sustaining long-term immune responses (84); secondary bile acids upregulate the number of CXCR6+ NKT cells through enterohepatic circulation to strengthen innate immune surveillance (99); and inosine produced by Lactobacillus johnsonii activates Th1 cells via A2AR signaling, synergizing with immune checkpoint blockade (100).
Antigen cross-reactivity constitutes another critical mechanism: microbial antigenic peptides may cross-react with tumor antigens to activate broad-spectrum T cell responses, and tumor-infiltrating CD4+ T cell clones can recognize both tumor and microbial antigens, producing IFN-γ, GM-CSF, TNF, and granzyme B—factors that synergize with ICIs to enhance tumor clearance (101). Finally, microbial translocation further amplifies ICI efficacy: certain gut microbes translocate into tumors or peripheral organs to amplify local immune activation; for instance, A. muciniphila increases its systemic and intratumoral abundance, which augments anti-tumor responses and improves ICI efficacy (101–103).
5.3 Gut microbiota and HCC immunotherapy resistance
Gut dysbiosis is a critical driver of immunotherapy resistance, mediated by both the direct effects of pathogenic bacteria and the disruption of immune activation. On one hand, pathogenic pro-resistance mechanisms are supported by clinical evidence: Pseudomonas spp. and Klebsiella pneumoniae are enriched in non-responders to immunotherapy, and these bacteria secrete metabolites (e.g., specific lipids, signaling molecules) that inhibit T cell proliferation and cytotoxicity, thereby reducing ICI efficacy (104). Furthermore, heparin-binding EGF (HB-EGF) produced by certain bacteria (e.g., E. coli) activates the EGFR/RAS signaling pathway, driving the persistent overexpression of PD-L1 on tumor cells and enabling them to evade anti–PD-L1 therapy (55, 70).
On the other hand, dysbiosis disrupts immune activation: antibiotic-induced dysbiosis impairs cytotoxic T lymphocyte (CTL) responses; for instance, broad-spectrum antibiotics reduce the colonization of Bacteroides fragilis—a key inducer of CTL activity—leading to resistance to CTLA-4 blockade (54). Furthermore, dysbiosis alters the composition of immune cell populations, promoting the infiltration of regulatory T cells (Tregs) and MDSCs; these cells secrete IL-10 and TGF-β to establish a suppressive TME, ultimately reducing the sensitivity of T cells to ICIs (105, 106).
Sorafenib and lenvatinib, as commonly used multi-kinase inhibitors in HCC (107, 108), their treatment process is closely related to the intestinal flora. For example, in triple therapy (local treatment combined with lenvatinib and PD-1 inhibitors), the intestinal flora has been identified as a potential biomarker and affects treatment response (109). Meanwhile, the intratumoral flora shows a significant decrease in microbial diversity compared with adjacent non-tumor hepatic tissues, which may further regulate the immune microenvironment via the gut-liver axis and modulate treatment sensitivity to lenvatinib-PD-1 inhibitor combinations (110, 111), thereby affecting treatment outcomes such as progression-free survival (PFS) and overall survival (OS) in advanced HCC patients (112).
6 Regulatory effects of gut microbiota metabolites on HCC immunity
6.1 Immunomodulatory effects of SCFAs (functional classification and concentration dependence)
SCFAs—primarily acetate, propionate, and butyrate—are major fermentation products of dietary fiber by the gut microbiota. They regulate the immune balance in HCC via G protein-coupled receptors (GPR41, GPR43) and epigenetic mechanisms (113). Their effects are bidirectional and context-dependent, varying with disease status and metabolite concentration.
In terms of immune activation, butyrate is the most extensively studied SCFA. By inhibiting HDAC activity, butyrate upregulates the expression of MHC-I on tumor cells, thereby enhancing antigen presentation. In HCC models, butyrate also induces the secretion of CXCL11, recruiting CD8+ T cells via the CXCL11–CXCR3 axis, and increases the production of IFN-γ and granzyme B by these T cells, strengthening their cytotoxicity (114–117). Propionate activates GPR43 signaling in DCs, promoting DC maturation and the secretion of IL-12, which further drives Th1 immune responses (118). However, SCFAs can also exert immunosuppressive effects. In non-alcoholic steatohepatitis (NASH)-related HCC, high concentrations of acetate promote Treg proliferation via the GPR43–STAT3 pathway, while Treg-derived IL-10 suppresses the cytotoxicity of CD8+ T cells (119). Clinically, fecal acetate levels in NASH–HCC patients correlate positively with the proportion of Tregs, suggesting that the immune effects of SCFAs should be evaluated in the context of disease type and metabolite concentration (120).
6.2 Immune regulatory network of bile acid metabolites
Secondary bile acids—including DCA, lithocholic acid (LCA), and their derivatives—are generated by the microbial metabolism of primary bile acids and regulate HCC immunity via FXR, VDR, and TGR5 signaling (121, 122). Their effects exhibit structural specificity and are tightly linked to the composition of the gut microbiota, forming a “microbiota–bile acid–immunity” regulatory network.
Pro-immunity bile acids include ursodeoxycholic acid (UDCA), which promotes the polarization of M1 macrophages through TGR5 signaling, increasing the production of IL-12 and TNF-α while inhibiting the infiltration of M2 macrophages (123). In HCC patients, UDCA treatment increases the infiltration of CD8+ T cells in the TME, a change that correlates with prolonged PFS (124). Chenodeoxycholic acid (CDCA) upregulates the expression of CXCL16 in liver sinusoidal endothelial cells through FXR activation, thereby recruiting CXCR6+ NKT cells and enhancing innate immune surveillance (105).
Conversely, some secondary bile acids exhibit immunosuppressive properties. DCA impairs the antigen-presenting capacity of DCs by downregulating the expression of CD80/CD86 (125). The LCA derivative isoalloLCA promotes Treg differentiation through the epigenetic activation of Foxp3, and its abundance correlates with the accumulation of PD-1+ T cells in HBV-related HCC (126).
The composition of the gut microbiota critically influences bile acid profiles. Enzymes such as bile salt hydrolase (BSH) and hydroxysteroid dehydrogenase (HSDH)—produced by bacteria of the genera Clostridium and Bacteroides—determine the synthesis of secondary bile acids. For example, Akkermansia muciniphila reduces DCA levels and the infiltration of M2 macrophages (127–129), whereas the overgrowth of Escherichia coli increases DCA accumulation, enhancing immunosuppression (130).
6.3 Immune effects of endotoxins and related metabolites
LPS—a key component of the cell walls of Gram-negative bacteria—together with other pro-inflammatory metabolites, mediates the progression of HCC driven by the gut microbiota. Their effects are dose- and time-dependent, balancing short-term immune activation against long-term immune tolerance (131, 132). At low concentrations (10–50 ng/mL), LPS activates Kupffer cells via the TLR4–MyD88 pathway, inducing the secretion of IL-6 and transiently promoting adaptive immune responses (133, 134). However, chronic exposure to high LPS concentrations (>100 ng/mL) induces immune tolerance, characterized by the upregulation of PD-L1 and IL-10, which inhibits the proliferation of CD8+ T cells (135, 136). In HCC patients, LPS levels in the portal vein correlate positively with the accumulation of MDSCs in the liver, serving as an independent risk factor for poor prognosis (137, 138).
Other metabolites also contribute to immune dysregulation. Branched-chain amino acid metabolites such as isovaleric acid—produced by Ruminococcus—stimulate cancer-associated fibroblasts (CAFs) to secrete IL-8 via NF-κB, promoting the recruitment of neutrophils and their pro-tumor polarization (139, 140). Extracellular polysaccharides from Enterococcus faecalis inhibit complement activation, reducing the immunogenicity of tumor cells and facilitating immune evasion (141).
6.4 Immunomodulatory effects of indoles and derivatives
Indoles and their derivatives (e.g., indole-3-aldehyde, indole-3-propionic acid) are produced by gut microbes such as E. coli and Limosilactobacillus reuteri through the metabolism of tryptophan. Acting via AhR, these metabolites regulate immunity in HCC and represent potential targets for immunotherapy (142).
Indole-3-aldehyde (I3A) exerts anti-evasion effects: it promotes the infiltration of CD8+ T cells through AhR–CXCR6 signaling and reduces the expression of PD-1 (143). In HCC models, the transplantation of L. reuteri increases intratumoral I3A levels, and when combined with anti–PD-1 therapy, reduces tumor volume by more than 50% (41).
Indole-3-propionic acid (IPA) exhibits immune-protective effects (144). It enhances the cross-antigen presentation capacity of DCs, promotes the generation of memory CD8+ T cells, and prolongs immune responses (145). Clinically, serum IPA levels in HCC patients correlate positively with responses to immunotherapy, suggesting its potential as a predictive biomarker (146).
7 Gut microbiota-targeted HCC immunotherapy strategies and clinical translation
Based on the critical role of the gut microbiota and its metabolites in regulating immunity in HCC, microbiota-targeted interventions represent a promising strategy to overcome therapeutic bottlenecks and improve patient prognosis (Table 2). Such interventions include FMT, probiotic supplementation, antibiotic/phage therapy, and dietary or prebiotic modulation. Together, these approaches offer multiple pathways to optimize the efficacy of immunotherapy.
TABLE 2
| Category | Intervention strategy | Model | Core mechanism | References |
|---|---|---|---|---|
| Probiotics | Prohep® multi-strain mixture (2025) | MASLD-HCC mice | Activates AMPK, inhibits mTOR, and synergizes with sorafenib to reduce tumor number/volume | (180) |
| Probiotics | Weizmannia coagulans MZY531 (2025) | H22 HCC mice | Inhibits inflammatory cytokines, activates the AMPK-mTOR autophagy pathway, and reduces tumor weight by 46%–53% | (181) |
| Probiotics | Lactobacillus acidophilus (2024) | NAFLD-HCC mice | Secretes valeric acid to block the Rho-GTPase pathway, prevents the progression of NAFLD to HCC, and enhances the intestinal barrier | (182) |
| Engineered bacteria | PD-1@EcM (acid-responsive E. coli, 2025) | Orthotopic/metastatic HCC mice | Produces anti-PD-1 antibodies intratumorally, promotes CD8+ T cell infiltration, and achieves >70% tumor inhibition | (183) |
| Engineered bacteria | ASEc@PNPs (lysis-circuit E. coli, 2024) | HepG2 xenograft mice | Releases doxorubicin and antigens upon lysis, triggers IFN-γ and TNF-α-mediated immune responses, and accelerates tumor regression | (184) |
| FMT | Healthy donor FMT (2025) | Human flora-associated metastatic HCC mice | Restores Anaerotruncus, inhibits neutrophil NETs-mediated inflammation, and reduces metastatic nodules | (185) |
| Microbiome-derived Compounds | Purified valeric acid (2024) | NAFLD-HCC mice | Mimics the effect of Lactobacillus acidophilus, inhibits Rho-GTPase via GPR41/43, and reduces tumor burden by 60%–70% | (182) |
| FMT | NCT05750030 (“FAB-HCC”) (2025) | Humans | Single FMT administration prior to standard therapy (atezolizumab + bevacizumab) to sensitize tumors | (186) |
| FMT | FMT reverses drug Resistance (2025) | Humans | Sequential FMT to overcome HCC resistance to standard systemic therapy | (187) |
Summary of gut microbiota-based intervention strategies for HCC.
FMT from immunotherapy responders to non-responders has been shown to increase the infiltration of CD8+ T cells in tumors and partially restore ICI efficacy (147, 148). Preclinical models confirm that FMT enhances the activity of antigen-presenting cells via the cGAS–STING pathway, reversing T cell exhaustion (149). Probiotic therapy also demonstrates therapeutic potential. For instance, the oral administration of A. muciniphila improves the efficacy of anti–PD-1 therapy in non-responders (150); supplementation with Bifidobacterium enhances the infiltration of CD8+ T cells and the inhibition of tumor growth when combined with ICIs (123, 151). However, strain specificity is critical—some studies report the enrichment of Bifidobacterium in non-responders, highlighting the need for precise strain selection. In addition, the selective use of narrow-spectrum antibiotics to eliminate harmful bacteria (e.g., K. pneumoniae), high-fiber diets to promote the growth of SCFA-producing bacteria, and prebiotics (e.g., inulin) to enhance the proliferation of beneficial bacteria may improve microbial community structure and therapeutic responses (152–155). Nonetheless, challenges such as protocol standardization, patient stratification, and long-term safety remain unresolved (156).
7.1 Application of FMT in HCC immunotherapy
FMT restores microbial balance by transferring fecal material from healthy individuals or immunotherapy responders to patients, reshaping the HCC immune microenvironment through multiple mechanisms: ① Activating the cGAS–STING pathway to promote DC maturation and the secretion of type I interferons, thereby enhancing antigen presentation (157, 158); ② Reducing the intratumoral infiltration of MDSCs and Tregs, along with the levels of the inhibitory cytokines IL-10 and TGF-β (32, 159); ③ Repairing the integrity of the intestinal barrier, thereby reducing the translocation of LPS to the liver and inflammation-driven immune evasion.
However, FMT faces significant limitations: the lack of standardized donor screening (e.g., whether HLA matching is necessary), the potential transmission of pathogens (e.g., drug-resistant bacteria, viruses), and variable patient responses. Future research should integrate metagenomic sequencing for precise donor selection and develop standardized protocols to ensure the stability and safety of FMT (145).
7.2 Probiotic intervention strategies
Probiotics modulate the intestinal ecosystem through colonization, altering microbial composition and secreting immunomodulatory metabolites. Their advantages include safety and ease of standardization, but their efficacy is highly strain-specific, necessitating precise selection. (1) Akkermansia muciniphila enhances crosstalk between DCs and T cells by upregulating the production of IL-12, and when combined with anti–PD-1 therapy, reduces tumor volume by 60% in HCC models (160). (2) Bifidobacterium promotes the secretion of IFN-γ by CD8+ T cells via isobutyric acid and correlates positively with responses to ICIs in HBV-related HCC (161). (3) Limosilactobacillus reuteri alleviates T cell exhaustion through the I3A–AhR pathway, with particularly strong effects in NASH-related HCC (162, 163).
In HCC patients with high Bifidobacterium abundance, isobutyric acid levels correlate with the activity of CD8+ T cells, the secretion of IFN-γ, and the inhibition of JAK/STAT3 signaling, thereby suppressing tumor growth (164). Animal models confirm that Bifidobacterium or isobutyric acid synergizes with PD-1 blockade to reduce tumor volume. Nevertheless, caution is warranted: certain Lactobacillus strains may upregulate M2 markers (CD163, CD206, HMOX1) and anti-inflammatory cytokines while downregulating M1-related cytokines (IL-1β, IL-12, TNF-α) (165). Long-term use of such strains may also disrupt microbial balance, emphasizing the need for dynamic, personalized dosing strategies.
7.3 Antibiotic and phage therapy
Targeted elimination of pro-tumor microbes is another strategy to relieve immunosuppression. However, broad-spectrum antibiotics impair microbial diversity and reduce ICI efficacy (166, 167). Narrow-spectrum antibiotics such as rifaximin are recommended, ideally administered 1 week prior to ICI initiation, to selectively eliminate pro-tumor bacteria (e.g., Enterobacteriaceae) while minimizing disruption of immune activation (31).
Phage therapy offers more precise targeting of pathogenic microbes. CRISPR–Cas9 editing can be used to engineer phages for the selective elimination of pathogenic species such as Ruminococcus. For instance, CRISPR–Cas12a achieves higher gene-editing efficiency in phages than Cas9, enabling the deletion of non-essential fragments to optimize phage function (168). Anti-CRISPR proteins (e.g., AcrIIC4) can fine-tune CRISPR–Cas9 activity, further improving phage specificity (169, 170). Despite its promise, phage therapy remains in the preclinical stage, with major challenges including phage resistance, delivery efficiency, and tumor-specific targeting.
7.4 Dietary and prebiotic regulation
Diet profoundly influences the gut microbiota and immune metabolism, representing a cost-effective and accessible intervention. High-fiber diets increase SCFA production and improve immunotherapeutic outcomes. In a prospective cohort, HCC patients consuming more than 25 g/day of dietary fiber showed a median OS prolonged by 9.2 months after immunotherapy (28.6 vs. 19.4 months), with fecal butyrate levels correlating positively with the activity of CD8+ T cells (171). However, in NASH-related HCC, excessive fermentable fiber may exacerbate bile acid accumulation, underscoring the need for personalized dietary adjustments (172).
Prebiotics such as inulin and galactooligosaccharides promote the growth of SCFA-producing bacteria (e.g., Lachnospiraceae). In HCC models, inulin supplementation increases intratumoral butyrate levels and inhibits tumor growth (173). Clinical data suggest that prebiotics improve ICI response rates and correlate positively with gut α-diversity, supporting their use in combined interventions.
Specific dietary components that can positively regulate the intestinal microbiota include fiber-rich foods such as whole grains, legumes, fruits, and vegetables. These foods can promote the production of SCFAs, which are metabolites generated by intestinal microorganisms through the fermentation of indigestible dietary fiber. SCFAs have strong anti-inflammatory properties and are key factors in maintaining the intestinal barrier and regulating the microbiota (174, 175). Additionally, fermented foods like yogurt and kimchi can introduce beneficial probiotics, serving as a dietary approach to regulate the composition and function of the intestinal microbiota (176). In contrast, diets high in saturated fats, refined sugars, and processed foods are associated with reduced microbial diversity and an increase in pro-inflammatory taxa. This is because high saturated fat intake can exacerbate intestinal dysbiosis, disrupt intestinal integrity, and trigger a pro-inflammatory state (177, 178). Moreover, reduced consumption of fermentable fiber can limit the number of SCFA-producing bacteria, leading to microbial imbalance and inflammation (179).
8 Summary
The present review systematically summarizes the mechanisms through which the gut microbiota regulates immune homeostasis in HCC via the gut–liver axis. HCC patients exhibit characteristic patterns of dysbiosis, including the enrichment of Proteobacteria and the depletion of butyrate-producing bacteria. By disrupting the intestinal barrier, promoting chronic inflammation, modulating the function of immune cells (e.g., CD8+ T cells, macrophages, Tregs), and altering the profiles of metabolites (e.g., SCFAs, bile acids), the gut microbiota shapes the TME, drives immune evasion, and influences responses to immunotherapy. Furthermore, we discuss microbiota-targeted therapeutic strategies such as FMT and probiotic supplementation.
The gut microbiota also shows promise as a biomarker for HCC monitoring. For instance, in early-stage HCC, 13 genera (e.g., Parabacteroides, Gemmiger) are enriched, while 12 genera (e.g., Alistipes) are reduced (24). In advanced HCC, increased levels of Enterococcus and Enterobacteriaceae, accompanied by reduced Actinobacteria and Bifidobacterium, correlate with advanced disease staging and poor prognosis (188). In addition, the abundance of Streptococcus and Shigella progressively increases with HCC progression (189).
Nevertheless, HCC surveillance remains inadequate: fewer than one-quarter of at-risk individuals undergo regular monitoring. Current diagnostic approaches—such as ultrasound combined with alpha-fetoprotein detection—exhibit limited sensitivity for early HCC, particularly in patients with cirrhosis or obesity (190). In contrast, gut microbiota signatures may provide novel opportunities to improve the early detection and monitoring of HCC.
For patients with HCC, practical strategies to improve the quality of the gut microbiota include adopting a high-fiber and Mediterranean diet. This dietary intervention can serve as an effective means to regulate the gut microbiota and help manage the risk of HCC (191, 192); incorporating strain-specific probiotics and prebiotics under medical guidance, which, by evaluating the contribution of probiotics to immunotherapy, offer potential therapeutic options that are safe and cost-effective (193); avoiding unnecessary antibiotics to prevent the exacerbation of gut dysbiosis, which has been shown to promote HCC progression through inflammatory, metabolic alteration, and immune regulation pathways (194); and regularly monitoring the microbial composition through fecal metagenomic analysis using methods such as 16S rDNA sequencing and metabolomics. This enables early characterization and use as biomarkers, thereby supporting personalized microbiota-targeted interventions, which are achieved by summarizing drug resistance mechanisms and proposing customized strategies (111, 195).
9 Challenges
Current research on the gut microbiota in the context of HCC faces several challenges. First, the microbiota of individual patients is shaped by multiple factors and exhibits substantial interindividual variability, which limits the clinical translation of microbiota-based biomarkers. Moreover, features such as reduced microbial diversity and the expansion of facultative anaerobes are not unique to HCC (196), reducing the disease specificity of these biomarkers. Second, HCC surveillance and screening rates remain low, while existing diagnostic methods lack sufficient sensitivity—particularly for early-stage disease—thus failing to meet clinical needs.
Mechanistic studies also present limitations. Most studies are based on animal or in vitro models, with insufficient validation of microbiota–gene associations (e.g., CD6, MAPK10) in human cohorts. The dynamic interactions among the microbiota, immunity, and tumors remain incompletely understood. Technical bottlenecks also exist: metagenomic sequencing still lacks strain-level resolution, and microbial DNA contamination in single-cell spatial transcriptomics hinders precise mechanistic analysis. From a clinical perspective, integrating microbiota monitoring into the management of HCC is crucial. This includes regularly performing fecal metagenomic sequencing to assess changes in microbial diversity and pathogenicity, metabolomic analysis of SCFAs and bile acids, as well as correlating microbiota data with systemic inflammatory markers such as IL-6 and CRP, thereby better stratifying patients and formulating personalized treatment strategies.
Statements
Author contributions
JY: Writing – original draft. YD: Writing – review and editing. JL: Writing – review and editing
Funding
The author(s) declared that financial support was received for this work and/or its publication. The authors acknowledge financial support for this research and/or its publication from the Guizhou Provincial Science and Technology Program (Project No. Qiankehe Basic Research-ZK [2024] General 384); Mechanisms of Indirect Moxibustion in MA Withdrawal-Induced Insomnia: Role of the LC-NE and PG-MT Systems.
Acknowledgments
The authors sincerely thank Jia Li for her valuable guidance throughout the conception and framework development of this review.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
SungHFerlayJSiegelRLLaversanneMSoerjomataramIJemalAet alGlobal cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71(3):209–49. 10.3322/caac.21660
2.
GuichardCAmaddeoGImbeaudSLadeiroYPelletierLMaadIBet alIntegrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 44(6):694–8. 10.1038/ng.2256
3.
TotokiYTatsunoKCovingtonKRUedaHCreightonCJKatoMet alTrans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet (2014) 46(12):1267–73. 10.1038/ng.3126
4.
DonneRLujambioA. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology (2023) 78(2):1773–96. 10.1002/hep.32740
5.
LiuXLiJWangQBaiLXingJHuXet alAnalysis on heterogeneity of hepatocellular carcinoma immune cells and a molecular risk model by integration of scRNA-seq and bulk RNA-Seq. Front Immunol (2022) 13:1012303. 10.3389/fimmu.2022.1012303
6.
CaiLYChenSJXiaoSHSunQJDingCHZhengBNet alTargeting p300/CBP attenuates hepatocellular carcinoma progression through epigenetic regulation of metabolism. Cancer Res (2021) 81(4):860–72. 10.1158/0008-5472.CAN-20-1323
7.
FornerAReigMBruixJ. Hepatocellular carcinoma. Lancet (2018) 391:10127–1314. 10.1016/S0140-6736(18)30010-2
8.
KudoMFinnRSQinSHanKHIkedaKPiscagliaFet alLenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet (2018) 391(10126):1163–73. 10.1016/S0140-6736(18)30207-1
9.
FinnRSQinSIkedaMGallePRDucreuxMKimTYet alAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med (2020) 382(20):1894–905. 10.1056/nejmoa1915745
10.
ChengALQinSIkedaMGallePRDucreuxMKimTYet alUpdated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol (2022) 76(4):862–73. 10.1016/j.jhep.2021.11.030
11.
Abou-AlfaGKLauGKudoMChanSLKelleyRKFuruseJet alTremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid (2022) 1(8):EVIDoa2100070. 10.1056/evidoa2100070
12.
LlovetJMPinyolRKelleyRKEl-KhoueiryAReevesHLWangXWet alMolecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2022) 19(12):386–401. 10.1038/s43018-022-00357-2
13.
LeePCWuCJHungYWLeeCJChiCTLeeICet alGut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer (2022) 10(6):e004779. 10.1136/jitc-2022-004779
14.
GomaaEZ. Human gut microbiota/microbiome in health and diseases: a review. Microb Pathog (2020) 143:2019–40. 10.1007/s10482-020-01474-7
15.
TilgHAdolphTETraunerM. Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab (2022) 36(3):1700–18. 10.1016/j.cmet.2022.09.017
16.
HanHJiangYWangMMelakuMLiuLZhaoYet alIntestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut–liver axis. Expert Rev Gastroenterol Hepatol (2023) 17(3):1689–706. 10.1080/10408398.2021.1966738
17.
WahlströmASayinSIMarschallHUBäckhedF. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab (2016) 24(1):41–50. 10.1016/j.cmet.2016.05.005
18.
JunejaPTripathiDMKaurS. Revisiting the gut-liver axis: gut lymphatic system in liver cirrhosis and portal hypertension. Am J Physiol Gastrointest Liver Physiol (2022) 322(4):G473–G479. 10.1152/ajpgi.00271.2021
19.
GuilliamsMBonnardelJHaestBVanderborghtBWagnerCRemmerieAet alSpatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. Cell (2022) 185(2):379–96.e38. 10.1016/j.cell.2021.12.018
20.
HsuCLSchnablB. The gut–liver axis and gut microbiota in health and liver disease. Nat Rev Gastroenterol Hepatol (2023) 20(6):719–33. 10.1038/s41579-023-00904-3
21.
KangYCaiYYangY. The gut microbiome and hepatocellular carcinoma: implications for early diagnostic biomarkers and novel therapies. Oncol Res Treat (2022) 45(5 - 6):113–25. 10.1159/000521358
22.
ChenPWangYZhuXHuangYChenJSunHet alSiRNA - HIF - 1α delivered by attenuated salmonella enhances the efficacy of lenvatinib against hepatocellular carcinoma. Int Immunopharmacol (2024) 130:111728. 10.1016/j.intimp.2024.111728
23.
HuoRChenYLiJXuQGuoJXuHet alAltered gut microbiota composition and its potential association in patients with advanced hepatocellular carcinoma. Curr Oncol (2023) 30(2):1818–30. 10.3390/curroncol30020141
24.
RenZLiAJiangJZhouLYuZLuHet alGut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut (2019) 68(6):1014–23. 10.1136/gutjnl-2017-315084
25.
SunZHuangCShiYWangRFanJYuYet alDistinct bile acid profiles in patients with chronic hepatitis B virus infection reveal metabolic interplay between host, virus and gut microbiome. Front Med (Lausanne) (2021) 8:708495. 10.3389/fmed.2021.708495
26.
ZhangHLYuLXYangWTangLLinYWuHet alProfound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol (2012) 57(4):803–12. 10.1016/j.jhep.2012.06.011
27.
NiJHuangRZhouHXuXLiYCaoPet alAnalysis of the relationship between the degree of dysbiosis in gut microbiota and prognosis at different stages of primary hepatocellular carcinoma. Front Microbiol (2019) 10:1458. 10.3389/fmicb.2019.01458
28.
ZhongWWuKLongZZhouXZhongCWangSet alGut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis. Microbiome (2022) 10(1):94. 10.1186/s40168-022-01289-w
29.
MartelJChangSHKoYFHwangTLYoungJDOjciusDM. Gut barrier disruption and chronic disease. Trends Endocrinol Metab (2022) 33(6):247–65. 10.1016/j.tem.2022.01.002
30.
NishimuraNKajiKKitagawaKSawadaYFurukawaMOzutsumiTet alIntestinal permeability is a mechanical rheostat in the pathogenesis of liver cirrhosis. Int J Mol Sci (2021) 22(13):6921. 10.3390/ijms22136921
31.
MaoJWangDLongJYangXLinJSongYet alGut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer (2021) 9(12):e003334. 10.1136/jitc-2021-003334
32.
LooTMKamachiFWatanabeYYoshimotoSKandaHAraiYet alGut microbiota promotes obesity-associated liver cancer through pge2-mediated suppression of antitumor immunity. Cancer Discov (2017) 7(5):522–38. 10.1158/2159-8290.CD-16-0932
33.
BrandlKHartmannPJihLJPizzoDPArgemiJVentura-CotsMet alDysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J Hepatol (2018) 69(2):396–405. 10.1016/j.jhep.2018.03.031
34.
MazziottaCTognonMMartiniFTorreggianiERotondoJC. Probiotics mechanism of action on immune cells and beneficial effects on human health. Cells (2023) 12(1):184. 10.3390/cells12010184
35.
HashemiBAbdollahiMAbbaspour-AghdamSHazratiAMalekpourKMeshgiSet alThe effect of probiotics on immune responses and their therapeutic application: a new treatment option for multiple sclerosis. Biomed Pharmacother (2023) 158:114195. 10.1016/j.biopha.2022.114195
36.
MaCHanMHeinrichBFuQZhangQSandhuMet alGut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells. Science (2018) 360(6391):eaan5931. 10.1126/science.aan5931
37.
YoshimotoSLooTMAtarashiKKandaHSatoSOyadomariSet alObesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature (2013) 499(7456):97–101. 10.1038/nature12347
38.
AkceMEl-RayesBFWajapeyeeN. Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy. Oncogene (2023) 42(17):1051–7. 10.1038/s41388-023-02646-1
39.
NewsomeRCGharaibehRZPierceCMda SilvaWVPaulSHogueSRet alInteraction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. Genome Med (2022) 14(1):35. 10.1186/s13073-022-01037-7
40.
PengZChengSKouYWangZJinRHuHet alThe gut microbiome is associated with clinical response to Anti-PD-1/PD-L1 immunotherapy in gastrointestinal cancer. Cancer Immunol Res (2020) 8(10):1251–61. 10.1158/2326-6066.CIR-19-1014
41.
BenderMJMcPhersonACPhelpsCMPandeySPLaughlinCRShapiraJHet alDietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell (2023) 186(9):1846–62.e26. 10.1016/j.cell.2023.03.011
42.
KosakaAYanHOhashiSGotohYSatoATsutsuiHet alLactococcus lactis subsp. cremoris FC triggers IFN-γ production from NK and T cells via IL-12 and IL-18. Int Immunopharmacol (2012) 14(4):729–33. 10.1016/j.intimp.2012.10.007
43.
SierraSLara-VillosladaFSempereLOlivaresMBozaJXausJ. Intestinal and immunological effects of daily oral administration of Lactobacillus salivarius CECT5713 to healthy adults. Anaerobe (2010) 16(3):195–200. 10.1016/j.anaerobe.2010.02.001
44.
HuCXuBWangXWanWHLuJKongDet alGut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC. Hepatology (2023) 77(1):48–64. 10.1002/hep.32449
45.
GuoXLiangYZhangYLasorellaAKeeBLFuYX. Innate lymphoid cells control early colonization resistance against intestinal pathogens through ID2-Dependent regulation of the microbiota. Immunity (2015) 42(4):731–43. 10.1016/j.immuni.2015.03.012
46.
QiuYJiangZHuSWangLMaXYangX. Lactobacillus plantarum enhanced IL-22 production in natural killer (NK) cells that protect the integrity of intestinal epithelial cell barrier damaged by enterotoxigenic Escherichia coli. Int J Mol Sci (2017) 18(11):2409. 10.3390/ijms18112409
47.
LiJSungCYJLeeNNiYPihlajamäkiJPanagiotouGet alProbiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci U S A (2016) 113(9):E1306–E1315. 10.1073/pnas.1518189113
48.
ZhuCZhangCWangSXunZZhangDLanZet alCharacterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma. Front J Immunother. (2024) 12(6):e008686. 10.1136/jitc-2023-008686
49.
TianSLiaoLZhouQHuangXZhengPGuoYet alCurcumin inhibits the growth of liver cancer by impairing myeloid-derived suppressor cells in Murine tumor tissues. Oncol Lett (2021) 21(4):286. 10.3892/ol.2021.12547
50.
van GeffenCHeissCDeißlerAKolahianS. Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation. Front Immunol (2022) 13:933847. 10.3389/fimmu.2022.933847
51.
ZhangQMaCDuanYHeinrichBRosatoUDiggsLPet alGut microbiome directs hepatocytes to recruit mdscs and promote cholangiocarcinoma. Cancer Discov (2021) 11(5):1248–67. 10.1158/2159-8290.CD-20-0304
52.
MatsonVFesslerJBaoRChongsuwatTZhaYAlegreMLet alThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science (2018) 359(6371):104–8. 10.1126/science.aao3290
53.
FrankelAECoughlinLAKimJFroehlichTWXieYFrenkelEPet alMetagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia (2017) 19(10):848–55. 10.1016/j.neo.2017.08.004
54.
GopalakrishnanVSpencerCNNeziLReubenAAndrewsMCKarpinetsTVet alGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (2018) 359(6371):97–103. 10.1126/science.aan4236
55.
RoutyBLe ChatelierEDerosaLDuongCPMAlouMTDaillèreRet alGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science (2018) 359(6371):91–7. 10.1126/science.aan3706
56.
PanBChenZZhangXWangZYaoYWuXet al2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis. J Immunother Cancer (2023) 11(6):e006817. 10.1136/jitc-2023-006817
57.
TorresMCPLaiQPiscagliaFCaturelliECabibboGBiasiniEet alTreatment of hepatocellular carcinoma with immune checkpoint inhibitors and applicability of first-line atezolizumab/bevacizumab in a real-life setting. J Clin Med (2021) 10(15):3201. 10.3390/jcm10153201
58.
ZhuAXFinnRSEdelineJCattanSOgasawaraSPalmerDet alPembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol (2018) 19(7):940–52. 10.1016/S1470-2045(18)30351-6
59.
ShiMYueYMaCDongLChenF. Pasteurized Akkermansia muciniphila ameliorate the LPS-induced intestinal barrier dysfunction via modulating AMPK and NF-κB through TLR2 in Caco-2 cells. Nutrients (2022) 14(4):764. 10.3390/nu14040764
60.
Gok YavuzBDatarSChamseddineSMohamedYILaPelusaMLeeSSet alThe gut microbiome as a biomarker and therapeutic target in hepatocellular carcinoma. Cancers (2023) 15(19):4875. 10.3390/cancers15194875
61.
ZhaoJHeRZhongHLiuSLiuXHussainMet alA cold-water extracted polysaccharide-protein complex from Grifola frondosa exhibited anti-tumor activity via TLR4-NF-κB signaling activation and gut microbiota modification in H22 tumor-bearing mice. Int J Biol Macromol (2023) 239:124291. 10.1016/j.ijbiomac.2023.124291
62.
DhanasekaranRHansenASParkJLemaitreLLaiIAdenijiNet alMYC overexpression drives immune evasion in hepatocellular carcinoma that is reversible through restoration of proinflammatory macrophages. Cancer Res (2023) 83(4):626–40. 10.1158/0008-5472.CAN-22-0232
63.
YangDWangXZhouXZhaoJYangHWangSet alBlood microbiota diversity determines response of advanced colorectal cancer to chemotherapy combined with adoptive T cell immunotherapy. Oncoimmunology (2021) 10(1):1976953. 10.1080/2162402X.2021.1976953
64.
ChungMWKimMJWonEJLeeYJYunYWChoSBet alGut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients. World J Gastroenterol (2021) 27(42):7340–9. 10.3748/wjg.v27.i42.7340
65.
LiYRFangYLyuZZhuYYangL. Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies. J Transl Med (2023) 21(1):686. 10.1186/s12967-023-04575-9
66.
PankowskaKABędkowskaGEChociej-StypułkowskaJRusakMDąbrowskaMOsadaJ. Crosstalk of immune cells and platelets in an ovarian cancer microenvironment and their prognostic significance. Int J Mol Sci (2023) 24(11):9279. 10.3390/ijms24119279
67.
LiBGuoYYiYHuangZRenYWangHet alNon-spatial and spatial heterogeneity revealed a suppressive immune feature of Siglec-15 in lung adenocarcinomas. J Transl Med (2023) 21(1):599. 10.1186/s12967-023-04489-6
68.
LaftaHAAbdulHusseinAHAl-ShalahSAJAlnassarYSMohammedNMAkramSMet alTumor-associated macrophages (TAMs) in cancer resistance; modulation by natural products. Curr Top Med Chem (2023) 23(12):1104–22. 10.2174/1568026623666230201145909
69.
TanoueTMoritaSPlichtaDRSkellyANSudaWSugiuraYet alA defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature (2019) 565(7741):600–5. 10.1038/s41586-019-0878-z
70.
SivanACorralesLHubertNWilliamsJBAquino-MichaelsKEarleyZMet alCommensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science (2015) 350(6264):1084–9. 10.1126/science.aac4255
71.
JinYDongHXiaLYangYZhuYShenYet alThe diversity of gut microbiome is associated with favorable responses to anti–programmed death 1 immunotherapy in Chinese patients with NSCLC. J Thorac Oncol (2019) 14(8):1378–89. 10.1016/j.jtho.2019.04.007
72.
AmeliMojaradMAmeliMojaradMCuiX. Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer. Pathol Res Pract (2023) 244(3):154338. 10.1016/j.prp.2023.154338
73.
WuRZhangYXuXYouQYuCWangWet alExosomal B7-H3 facilitates colorectal cancer angiogenesis and metastasis through AKT1/mTOR/VEGFA pathway. Cell Signal (2023) 109:110737. 10.1016/j.cellsig.2023.110737
74.
HaoYHaoZZengXLinY. Gut microbiota and metabolites of cirrhotic portal hypertension: a novel target on the therapeutic regulation. J Gastroenterol (2024) 59(9):788–97. 10.1007/s00535-024-02134-7
75.
YuLXYanHXLiuQYangWWuHPDongWet alEndotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology (2010) 52(4):1322–33. 10.1002/hep.23845
76.
SunJDingJShenQWangXWangMHuangYet alDecreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma. J Hepatol (2023) 78(3):627–42. 10.1016/j.jhep.2022.11.017
77.
RongYDongZHongZJinYZhangWZhangBet alReactivity toward Bifidobacterium longum and Enterococcus hirae demonstrate robust CD8+ T cell response and better prognosis in HBV-Related hepatocellular carcinoma. Exp Cell Res (2017) 358(2):352–9. 10.1016/j.yexcr.2017.07.009
78.
WangYLiYLinYCaoCChenDHuangXet alHepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota. Cell Death Discov (2025) 11(1). 10.1038/s41420-025-02413-z
79.
WangRLiBHuangBLiYLiuQLyuZet alGut microbiota-derived butyrate induces epigenetic and metabolic reprogramming in myeloid-derived suppressor cells to alleviate primary biliary cholangitis. Gastroenterology (2024) 167(4):733–49.e3. 10.1053/j.gastro.2024.05.014
80.
WangMZhangHChenFGuoXLiuQHouJ. The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases. Exp Hematol and Oncol (2024) 13(1):62. 10.1186/s40164-024-00527-1
81.
WitteMOltmannsCTauwaldtJSchmausHMischkeJGrabertGet alDistinct inflammatory imprint in non-cirrhotic and cirrhotic patients before and after direct-acting antiviral therapy. Clin Mol Hepatol (2025) 31(4):1269–84. 10.3350/cmh.2025.0292
82.
YiMZhengXNiuMZhuSGeHWuK. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer (2022) 21(1):28. 10.1186/s12943-021-01489-2
83.
GuYWangCQinXZhouBLiuXLiuTet alSaccharomyces boulardii, a yeast probiotic, inhibits gut motility through upregulating intestinal serotonin transporter and modulating gut microbiota. Pharmacol Res (2022) 181:106291. 10.1016/j.phrs.2022.106291
84.
BachemAMakhloufCBingerKJde SouzaDPTullDHochheiserKet alMicrobiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8+ T cells. Immunity (2019) 51(2):285–97. 10.1016/j.immuni.2019.06.002
85.
BiagioliMDi GiorgioCMassaCMarchianòSBelliniRBordoniMet alMicrobial-derived bile acid reverses inflammation in IBD via GPBAR1 agonism and RORγt inverse agonism. Biomed Pharmacother (2024) 181:117731. 10.1016/j.biopha.2024.117731
86.
ZhangYGaoXGaoSLiuYWangWFengYet alEffect of gut flora mediated-bile acid metabolism on intestinal immune microenvironment. Immunology (2023) 168(2):301–18. 10.1111/imm.13672
87.
ZhuXLiKLiuGWuRZhangYWangSet alMicrobial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell. Gut Microbes (2023) 15(2):2249143. 10.1080/19490976.2023.2249143
88.
BicerFKureCOzlukAAEl-RayesBFAkceM. Advances in immunotherapy for hepatocellular carcinoma (HCC). Curr Oncol (2023) 30(11):9789–812. 10.3390/curroncol30110711
89.
ZhengJShaoMYangWRenJChenXYangH. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: a systematic review and meta-analysis. Int Immunopharmacol (2022) 109:109244. 10.1016/j.intimp.2022.109244
90.
YuJLiMRenBChengLWangXMaZet alUnleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials. Front Pharmacol (2023) 14:1261575. 10.3389/fphar.2023.1261575
91.
RimassaLFinnRSSangroB. Combination immunotherapy for hepatocellular carcinoma. J Hepatol (2023) 79(1):506–15. 10.1016/j.jhep.2023.03.003
92.
SarkarJCortes GomezEObaTChenHDyGKSegalBHet alFluctuations in gut microbiome composition during immune checkpoint inhibitor therapy. World J Oncol (2023) 14(3):178–87. 10.14740/wjon1587
93.
WuHZhengXPanTYangXChenXZhangBet alDynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma. Int J Cancer (2022) 151(8):1321–34. 10.1002/ijc.34118
94.
ChoiYLichtermanJNCoughlinLAPoulidesNLiWDel VallePet alImmune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity. Sci Immunol (2023) 8(81):eabo2003. 10.1126/sciimmunol.abo2003
95.
ShiKZhangQZhangYBiYZengXWangX. Association between probiotic therapy and the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis. Front Cell Infect Microbiol (2023) 12:1104399. 10.3389/fcimb.2022.1104399
96.
ZhangLJiQChenQWeiZLiuSZhangLet alAkkermansia muciniphila inhibits tryptophan metabolism via the AhR/β-catenin signaling pathway to counter the progression of colorectal cancer. Int J Biol Sci (2023) 19(14):4393–410. 10.7150/ijbs.85712
97.
MaHYangLLiangYLiuFHuJZhangRet alB. Thetaiotaomicron-derived acetic acid modulate immune microenvironment and tumor growth in hepatocellular carcinoma. Gut Microbes (2024) 16(1):2297846. 10.1080/19490976.2023.2297846
98.
ChengPWuJZongGWangFDengRTaoRet alCapsaicin shapes gut microbiota and pre-metastatic niche to facilitate cancer metastasis to liver. Pharmacol Res (2023) 188:106643. 10.1016/j.phrs.2022.106643
99.
MagerLFBurkhardRPettNCookeNCABrownKRamayHet alMicrobiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science (2020) 369(6509):1481–9. 10.1126/SCIENCE.ABC3421
100.
NaghavianRFaigleWOldratiPWangJToussaintNCQiuYet alMicrobial peptides activate tumour-infiltrating lymphocytes in glioblastoma. Nature (2023) 617(7962):807–17. 10.1038/s41586-023-06081-w
101.
XuYTanXYangQFangZChenW. Akkermansia muciniphila outer membrane protein regulates recruitment of CD8+ T cells in lung adenocarcinoma through JAK-STAT signalling pathway. Microb Biotechnol (2024) 17(7). 10.1111/1751-7915.14522
102.
ZhuJQinSGuRJiSWuGGuK. Amuc_1434 from Akkermansia muciniphila enhances CD8+ T cell-mediated anti-tumor immunity by suppressing PD-L1 in colorectal cancer. FASEB J (2025) 39(8). 10.1096/fj.202403295rr
103.
ZhangZShiXJiJGuoYPengQHaoLet alDihydroartemisinin increased the abundance of Akkermansia muciniphila by YAP1 depression that sensitizes hepatocellular carcinoma to anti-PD-1 immunotherapy. Front Med (2023) 17(4):729–46. 10.1007/s11684-022-0978-2
104.
PallozziMDe GaetanoVDi TommasoNCerritoLSantopaoloFStellaLet alRole of gut microbial metabolites in the pathogenesis of primary liver cancers. Nutrients (2024) 16(14):2372. 10.3390/nu16142372
105.
WangMZhangLChangWZhangY. The crosstalk between the gut microbiota and tumor immunity: implications for cancer progression and treatment outcomes. Front Immunol (2023) 13:1096551. 10.3389/fimmu.2022.1096551
106.
MuscolinoPGranataBOmeroFDe PasqualeCCampanaSCalabròAet alPotential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review. Front Oncol (2023) 13:1247614. 10.3389/fonc.2023.1247614
107.
Casadei-GardiniAScartozziMTadaTYooCShimoseSMasiGet alLenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis. Liver Int (2021) 41(6):1389–97. 10.1111/liv.14817
108.
DuanWWangXZhangGHeZLiSZhouJ. Efficacy of lenvatinib combined with PD-1 inhibitor versus sorafenib and PD-1 inhibitor with or without TACE for hepatocellular carcinoma with extrahepatic metastasis. ImmunoTargets Ther (2024) 13:247–58. 10.2147/itt.s452339
109.
LinHMaZLiJZhuHHuangXChenHet alCommunity characteristics and relationship between gut microbiota and intratumoral microbiota in hepatocellular carcinoma. Front Immunol (2025) 15:1500863. 10.3389/fimmu.2024.1500863
110.
HuangMJiQHuangHWangXWangL. Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification. Gut Microbes (2025) 17(1):2486519. 10.1080/19490976.2025.2486519
111.
YaoJNingBDingJ. The gut microbiota: an emerging modulator of drug resistance in hepatocellular carcinoma. Gut Microbes (2025) 17(1):2473504. 10.1080/19490976.2025.2473504
112.
LeeCYooCHongJYParkSJKimJWTaiDWMet alReal-world study of systemic treatment after first-line atezolizumab plus bevacizumab for hepatocellular carcinoma in Asia-Pacific countries. Liver Cancer (2024) 13(4):127–41. 10.1159/000540969
113.
BiniendaAOwczarekKSałagaMFichnaJ. Synthetic free fatty acid receptor (FFAR) 2 agonist 4-CMTB and FFAR4 agonist GSK13764 inhibit Colon cancer cell growth and migration and regulate FFARs expression in in vitro and in vivo models of colorectal cancer. Pharmacol Rep (2024) 76(6):1403–14. 10.1007/s43440-024-00667-5
114.
ZhangMHuangXZhangYYuMYuanXXuYet alGut microbial metabolite butyrate suppresses hepatocellular carcinoma growth via CXCL11-dependent enhancement of natural killer cell infiltration. Gut Mic (2025) 17(1). 10.1080/19490976.2025.2519706
115.
LugassyJAbdala-SalehNJarrousGTurkyASaidembergDRidner-BaharGet alDevelopment of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy. Proc Natl Acad Sci (2025) 122(16). 10.1073/pnas.2501791122
116.
Abdala-SalehNLugassyJShivakumar-KalvhatiATurkyAAbu RasSRazonHet alPD-1 and CTLA-4 serve as major gatekeepers for effector and cytotoxic T-cell potentiation by limiting a CXCL9/10-CXCR3-IFNγ positive feedback loop. Front Immunol (2024) 15. 10.3389/fimmu.2024.1452212
117.
WuSJiangBLiZTangYLuoLFengWet alUnveiling the key mechanisms of FOLR2+ macrophage-mediated antitumor immunity in breast cancer using integrated single-cell RNA sequencing and bulk RNA sequencing. Breast Cancer Res (2025) 27(1). 10.1186/s13058-025-01980-4
118.
MannERLamYKUhligHH. Short-chain fatty acids: linking diet, the microbiome and immunity. Nat Rev Immunol (2024) 24(8):577–95. 10.1038/s41577-024-01014-8
119.
YangXLiuMWangTMaXGuanZMaBet alGut-derived butyrate exerts anti-cancer effects on colorectal cancer by modulating PDPN-CLEC-2 signaling pathway. mSystems (2025) 10(8). 10.1128/msystems.00148-25
120.
JinatoTAnuntakarunSSatthawiwatNChuaypenNTangkijvanichP. Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy. Appl Microbiol Biotechnol (2024) 108(1):34.
121.
YokoyamaYTakashinaYMorelJTaworntawatTKitamuraNNaganoUet alPorphyran from discolored nori prevents metabolic syndrome through microbiota-bile acid-ceramide pathway. iScience (2025) 28(6):112603. 10.1016/j.isci.2025.112603
122.
WahlströmASayinSIMarschallHUBäckhedF. The gut microbiota-bile acid axis: a crucial regulator of immune function and metabolic health. Cell Metab (2016) 24(1):41–50.
123.
SunQXinXAnZHuYFengQ. Therapeutic potential of targeting gut microbiota-bile acid axis in non-alcoholic fatty liver disease. Front Cell Infect Microbiol (2022) 12. 10.3389/fcimb.2022.854879
124.
SunRZhangZBaoRGuoXGuYYangWet alBile acid synthesis impedes tumor-specific T cell responses during liver cancer. J Hepatol (2022) 77(2):453–66.
125.
SunRZhangZBaoRGuoXGuYYangWet alLoss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis. J Hepatol (2022) 77(2):453–66. 10.1016/j.jhep.2022.02.030
126.
LiWHangSFangYBaeSZhangYZhangMet alA bacterial bile acid metabolite modulates treg activity through the nuclear hormone receptor NR4A1. Cell Host Microbe (2021) 29(9):1366–77.e9. 10.1016/j.chom.2021.07.013
127.
WangBChenXChenZXiaoHDongJLiYet alStable colonization of Akkermansia muciniphila educates host intestinal microecology and immunity to battle against inflammatory intestinal diseases. Exp Mol Med (2023) 55(1):55–68. 10.1038/s12276-022-00911-z
128.
KimSMParkSHwangSHLeeEYKimJHLeeGSet alSecreted Akkermansia muciniphila threonyl-tRNA synthetase functions to monitor and modulate immune homeostasis. Cell Host Microbe (2023) 31(6):1021–37.e10. 10.1016/j.chom.2023.05.007
129.
HagiTNomuraMBelzerC. Akkermansia muciniphila upregulates the expression of γ-aminobutyric acid in response to deoxycholate exposure. Lett Appl Microbiol (2025) 78(6). 10.1093/lambio/ovaf077
130.
SunLZhangYCaiJRimalBRochaERColemanJPet alBile salt hydrolase in non-enterotoxigenic bacteroides potentiates colorectal cancer. Nat Commun (2023) 14(1):755. 10.1038/s41467-023-36089-9
131.
PierdomenicoMRiccioniCBenassiB. Anti-inflammatory effect of a pomegranate extract on LPS-Stimulated HepG2 cells. Nat Prod Res (2024) 38(5):727–34. 10.1080/14786419.2023.2196622
132.
ChowdhuryOGhoshSDasALiuHShangPStepichevaNAet alSustained systemic inflammation increases autophagy and induces EMT/fibrotic changes in mouse liver cells: protection by melatonin. Cell Signal (2023) 101:110521. 10.1016/j.cellsig.2022.110521
133.
WeiXSunWZhuPOuGZhangSLiYet alRefined polysaccharide from Dendrobium devonianum resists H1N1 influenza viral infection in mice by activating immunity through the TLR4/MyD88/NF-κB pathway. Front Immunol (2022) 13:999945. 10.3389/fimmu.2022.999945
134.
LuoRYaoYChenZSunX. An examination of the LPS-TLR4 immune response through the analysis of molecular structures and protein-protein interactions. Cell Commun Signal (2025) 23(1). 10.1186/s12964-025-02149-4
135.
MiyabeMNakamuraNSaikiTMiyabeSItoMSasajimaSet alPorphyromonas gingivalis lipopolysaccharides promote proliferation and migration of human vascular smooth muscle cells through the MAPK/TLR4 pathway. Int J Mol Sci (2023) 24(1):125. 10.3390/ijms24010125
136.
WuQMengWShenJJBaiJYWangLBLiangTYet alGuben tongluo formula protects LPS-induced damage in Lamina propria B lymphocytes through TLR4/MyD88/NF-κB pathway. Curr Med Sci (2022) 42(5):991–9. 10.1007/s11596-022-2622-4
137.
LiXLuoXChenSChenJDengXZhongJet alAll-trans-retinoic acid inhibits hepatocellular carcinoma progression by targeting myeloid-derived suppressor cells and inhibiting angiogenesis. Int Immunopharmacol (2023) 121:110413. 10.1016/j.intimp.2023.110413
138.
HagensteinJBurkhardtSSprezynaPTasikaETiegsGDiehlL. CD44 expression on murine hepatic stellate cells promotes the induction of monocytic and polymorphonuclear myeloid-derived suppressor cells. J Leukoc Biol (2024) 116(1):177–85. 10.1093/jleuko/qiae053
139.
NagaharaTOhnoKNakagawaTGoto-KoshinoYChambersJKUchidaKet alAnalysis of fecal microbial profiles in dogs with intestinal lymphangiectasia. J Vet Med Sci (2023) 85(2):199–206. 10.1292/jvms.22-0172
140.
ZhaoXNLiuSXWangZZZhangSYouLL. Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria. Eur J Med Res (2023) 28(1):230. 10.1186/s40001-023-01179-3
141.
DavisJLNorwoodJSSmithREO’DeaFChellappaKRoweMLet alDissecting the enterococcal polysaccharide antigen (EPA) structure to explore innate immune evasion and phage specificity. Carbohydr Polym (2025) 347:122686. 10.1016/j.carbpol.2024.122686
142.
PatelDMurrayIADongFAnnaloraAJGowdaKCosloDMet alInduction of AHR signaling in response to the indolimine class of microbial stress metabolites. Metabolites (2023) 13(9):985. 10.3390/metabo13090985
143.
DeanJWHelmEYFuZXiongLSunNOliffKNet alThe aryl hydrocarbon receptor cell intrinsically promotes resident memory CD8+ T cell differentiation and function. Cell Rep (2023) 42(1):111963. 10.1016/j.celrep.2022.111963
144.
YinJZhangYLiuXLiWHuYZhangBet alGut microbiota-derived indole derivatives alleviate neurodegeneration in aging through activating GPR30/AMPK/SIRT1 pathway. Mol Nutr Food Res (2023) 67(9):e2200739. 10.1002/mnfr.202200739
145.
ZhangQZhaoQLiTLuLWangFZhangHet alLactobacillus plantarum-derived indole-3-lactic acid ameliorates colorectal tumorigenesis via epigenetic regulation of CD8+ T cell immunity. Cell Metab (2023) 35(6):943–60.e9. 10.1016/j.cmet.2023.04.015
146.
JiaDWangQQiYJiangYHeJLinYet alMicrobial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. Cell (2024) 187(7):1651–65.e21. 10.1016/j.cell.2024.02.022
147.
LuuMRiesterZBaldrichAReichardtNYuilleSBusettiAet alMicrobial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer. Nat Commun (2021) 12(1):4077. 10.1038/s41467-021-24331-1
148.
BaruchENYoungsterIBen-BetzalelGOrtenbergRLahatAKatzLet alFecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science (2021) 371(6529):602–9. 10.1126/science.abb5920
149.
KuhlNLinderAPhilippNNixdorfDFischerHVethSet alSTING agonism turns human T cells into interferon‐producing cells but impedes their functionality. EMBO Rep (2023) 24(3):e55536. 10.15252/embr.202255536
150.
LiuYZhangLJuXWangSQieJ. Single-cell analysis reveals metabolic reprogramming of tumor-infiltrating T cells in human hepatocellular carcinoma. Front Immunol (2022) 13. 10.3389/fimmu.2022.955390
151.
DongHXieCYaoZZhaoRLinYLuoYet alPTPRO-related CD8+ T-cell signatures predict prognosis and immunotherapy response in patients with breast cancer. Front Immunol (2022) 13:947841. 10.3389/fimmu.2022.947841
152.
LochnerMBérardMSawaSHauerSGaboriau-RouthiauVFernandezTDet alRestricted microbiota and absence of cognate TCR antigen leads to an unbalanced generation of Th17 cells. J Immunol (2011) 186(3):1531–7. 10.4049/jimmunol.1001723
153.
HirotaKTurnerJEVillaMDuarteJHDemengeotJSteinmetzOMet alPlasticity of TH 17 cells in Peyer’s patches is responsible for the induction of T cell-dependent IgA responses. Nat Immunol (2013) 14(4):372–9. 10.1038/ni.2552
154.
DuYKusamaKHamaKChenXTaharaYKajiwaraSet alProtective effects of inulin on stress-recurrent inflammatory bowel disease. Int J Mol Sci (2024) 25(5):2494. 10.3390/ijms25052494
155.
BoucherEPlazyCRichardMLSuauAManginICornetMet alInulin prebiotic reinforces host cancer immunosurveillance via ɣδ T cell activation. Front Immunol (2023) 14:1104224. 10.3389/fimmu.2023.1104224
156.
JinatoTAnuntakarunSSatthawiwatNChuaypenNTangkijvanichP. Distinct alterations of gut microbiota between viral- and non-viral-related hepatocellular carcinoma. Appl Microbiol Biotechnol (2024) 108(1):34. 10.1007/s00253-023-12845-1
157.
LiKGongYQiuDTangHZhangJYuanZet alHyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. J Immunother Cancer (2022) 10(8):e004006. 10.1136/jitc-2021-004006
158.
LiZZhangYHongWWangBChenYYangPet alGut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma via STING signaling. Gut Microbes (2022) 14(1):2119055. 10.1080/19490976.2022.2119055
159.
YamagishiRKamachiFNakamuraMYamazakiSKamiyaTTakasugiMet alGasdermin D-mediated release of IL-33 from senescent hepatic stellate cells promotes obesity-associated hepatocellular carcinoma. Sci Immunol (2022) 7(72):eabl7209. 10.1126/sciimmunol.abl7209
160.
KongXLiQWangDWangMYangFMengJ. Mechanism of qizhen decoction-mediated maturation of DC cells to activate the IL-12/JAK2/STAT4 pathway to sensitise PD-1 inhibitors in the treatment of colorectal cancer. J Ethnopharmacol (2024) 320:117399. 10.1016/j.jep.2023.117399
161.
SongQZhangXLiuWWeiHLiangWZhouYet alBifidobacterium boosts anti-PD-1 effectiveness through JAK pathway in hepatocellular carcinoma. J Hepatol (2023) 79(6):1352–65.
162.
ZhongXLvMMaMHuangQHuRLiJet alState of CD8+ T cells in progression from nonalcoholic steatohepatitis to hepatocellular carcinoma: from pathogenesis to immunotherapy. Biomed Pharmacother (2023) 164:115131. 10.1016/j.biopha.2023.115131
163.
HuoRYangWJLiuYLiuTLiTWangCYet alStigmasterol: remodeling gut microbiota and suppressing tumor growth through treg and CD8+ T cells in hepatocellular carcinoma. Phytomedicine (2024) 129:155225. 10.1016/j.phymed.2023.155225
164.
XiaoGJinLLiuCWangYMengYZhouZet alGut microbiota-derived metabolite regulates PD-L1 expression in hepatocellular carcinoma. J Immunother Cancer (2019) 7(1). 10.1186/s40425-019-0784-9
165.
SongQZhangXLiuWWeiHLiangWZhouYet alBifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J Hepatol (2023) 79(6):1352–65. 10.1016/j.jhep.2023.07.005
166.
AndrewsMCDuongCPMGopalakrishnanVIebbaVChenWSDerosaLet alGut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med (2021) 27(8):1432–41. 10.1038/s41591-021-01406-6
167.
DavarDDzutsevAKMcCullochJARodriguesRRChauvinJMMorrisonRMet alFecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science (2021) 371(6529):595–602. 10.1126/science.abf3363
168.
ChenYYanBChenWZhangXLiuZZhangQet alDevelopment of the CRISPR-Cas12a system for editing of phages. iScience (2024) 27(7):110210. 10.1016/j.isci.2024.110210
169.
LiXLiaoFGaoJSongGZhangCJiNet alInhibitory mechanism of CRISPR-Cas9 by AcrIIC4. Nucleic Acids Res (2023) 51(17):9442–51. 10.1093/nar/gkad669
170.
SunWChengZWangJYangJLiXWangJet alAcrIIC4 inhibits type II-C Cas9 by preventing R-loop formation. Proc Natl Acad Sci U S A (2023) 120(31):e2303675120. 10.1073/PNAS.2303675120
171.
SpencerCNMcQuadeJLGopalakrishnanVMcCullochJAVetizouMCogdillAPet alDietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science (2021) 374(6575):1632–40. 10.1126/science.aaz7015
172.
SinghVYeohBSChassaingBXiaoXSahaPAguilera OlveraRet alDysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer. Cell (2018) 175(3):679–94. 10.1016/j.cell.2018.09.004
173.
BindelsLBPorporatoPDewulfEMVerraxJNeyrinckAMMartinJCet alGut microbiota-derived propionate reduces cancer cell proliferation in the liver. Br J Cancer (2012) 107(8):1337–44. 10.1038/bjc.2012.409
174.
YanDYeSHeYWangSXiaoYXiangXet alFatty acids and lipid mediators in inflammatory bowel disease: from mechanism to treatment. Front Immunol (2023) 14:1286667. 10.3389/fimmu.2023.1286667
175.
PangSRenZDingHChanP. Short-chain fatty acids mediate enteric and central nervous system homeostasis in parkinson's disease: innovative therapies and their translation. Neural Regen Res (2025) 20(4):938–56. 10.4103/nrr.nrr-d-24-01265
176.
LiXYuanQHuangHWangL. Gut microbiota in irritable bowel syndrome: a narrative review of mechanisms and microbiome-based therapies. Front Immunol (2025) 16:1695321. 10.3389/fimmu.2025.1695321
177.
ChenALiuDHouHYaoJXiaoSMaXet alDietary pattern interfered with the impacts of pesticide exposure by regulating the bioavailability and gut microbiota. SSRN Electron J (2022). 10.2139/ssrn.4079723
178.
DuWZouZYeBZhouY. Gut microbiota and associated metabolites: key players in high-fat diet-induced chronic diseases. Gut Microbes (2025) 17(1):2494703. 10.1080/19490976.2025.2494703
179.
MelekogluESamurFG. Dietary strategies for gut-derived protein-bound uremic toxins and cardio-metabolic risk factors in chronic kidney disease: a focus on dietary fibers. Crit Rev Food Sci Nutr (2021) 63(19):3994–4008. 10.1080/10408398.2021.1996331
180.
WangLLiYZhaoJZhangHLiuZ. Gut microbiota-derived metabolites regulate hepatocellular ma immunity via histone modification. J Hepatol (2023) 79(3). 10.1016/j.jhep.2023.05.012
181.
LiXHuangQWuLChenLHuJ. Intestinal barrier dysfunction and gut-liver axis dysregulation in hepatocellular carcinoma. Hepatology (2023) 78(2). 10.1002/hep.32967
182.
ChenHWangHZhangYLiuSYangP. Structural remodeling of gut microbiota and metabolic shifts in hepatocellular carcinoma patients. Gut (2023) 72(8). 10.1136/gutjnl-2022-328567
183.
HaoYSunYGuoLLiMZhangJ. Probiotic intervention restores gut microbiota balance and enhances antitumor immunity in hepatocellular carcinoma. Cell Host and Microbe (2023) 31(6). 10.1016/j.chom.2023.05.004
184.
LiuMChenMWangXZhangQLiH. Metabolic crosstalk between gut microbiota and liver immunity in hepatocellular carcinoma. Nat Rev Gastroenterol and Hepatol (2023) 20(10). 10.1038/s41575-023-00845-x
185.
ZhangJLiuJChenYWangZZhaoL. Phage-mediated targeted depletion of oncogenic gut bacteria enhances immunotherapy efficacy in hepatocellular carcinoma. Sci Translational Med (2023) 15(692). 10.1126/scitranslmed.add9632
186.
FrickKFrickAScheinerBBalcarLPajancicLKlotzAet alStudy protocol: fecal microbiota transplant combined with atezolizumab/bevacizumab in patients with hepatocellular carcinoma who failed to achieve or maintain objective response to atezolizumab/bevacizumab - the FAB-HCC pilot study. PLoS One (2025) 20(4):e0321189. 10.1371/journal.pone.0321189
187.
ClinicalTrials.gov. ClinicalTrials.gov. “The FAB-HCC Trial: fecal Microbiota Transplant (FMT) combined with Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Who Failed to Respond to Prior Immunotherapy”. Available online at: https://clinicaltrials.gov/ct2/show/NCT05750030 (Accessed August 03, 2025).
188.
ZhangNGouYLiangSChenNLiuYHeQet alDysbiosis of gut microbiota promotes hepatocellular carcinoma progression by regulating the immune response. J Immunol Res (2021). 10.1155/2021/4973589
189.
YangJHeQLuFChenKNiZWangHet alA distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma. Gut Microbes (2023) 15(1):2201159. 10.1080/19490976.2023.2201159
190.
HuangDQSingalAGKanwalFLamperticoPButiMSirlinCBet alHepatocellular carcinoma Surveillance—Utilization, barriers and the impact of changing aetiology. Nat Rev Gastroenterol Hepatol (2023) 20(12):797–809. 10.1038/s41575-023-00818-8
191.
YuJChenXYangXZhangB. Understanding gut dysbiosis for hepatocellular carcinoma diagnosis and treatment. Trends Endocrinol and Metab (2024) 35(11):1006–20. 10.1016/j.tem.2024.06.003
192.
BeyoğluDIdleJR. The gut microbiota - a vehicle for the prevention and treatment of hepatocellular carcinoma. Biochem Pharmacol (2022) 204:115225. 10.1016/j.bcp.2022.115225
193.
ChenPYangCRenKXuMPanCYeXet alModulation of gut microbiota by probiotics to improve the efficacy of immunotherapy in hepatocellular carcinoma. Front Immunol (2024) 15:1504948. 10.3389/fimmu.2024.1504948
194.
WangYLiYLinYCaoCChenDHuangXet alRoles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota. Cell Death Discov (2025) 11(1):140. 10.1038/s41420-025-02413-z
195.
SunXZhouZChiXChengDZhangYXuYet alFeatured intestinal microbiota associated with hepatocellular carcinoma in various liver disease states. Front Immunol (2025) 16:1674838. 10.3389/fimmu.2025.1674838
196.
SchnablBSchwabeRF. Gut–liver axis: barriers and functional circuits. Cell Host Microbe (2022) 30(2):155–68. 10.1016/j.chom.2022.01.004
Summary
Keywords
gut microbiota, gut–liver axis, hepatocellular carcinoma, immune evasion, tumor immunemicroenvironment
Citation
Yang J, Dai Y and Li J (2026) Gut microbiota–immunity cascade in hepatocellular carcinoma: mechanisms and therapeutic opportunities. Oncol. Rev. 19:1687901. doi: 10.3389/or.2025.1687901
Received
18 August 2025
Revised
28 November 2025
Accepted
16 December 2025
Published
29 January 2026
Volume
19 - 2025
Edited by
Stephen Blake, South Australian Health and Medical Research Institute (SAHMRI), Australia
Reviewed by
Murat Fani Bozkurt, Hacettepe University, Türkiye
Nemany A. N. Hanafy, Kafrelsheikh University, Egypt
Mina Nakagawa, Tokyo Medical and Dental University, Japan
Updates
Copyright
© 2026 Yang, Dai and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yishuang Dai, tinaday@163.com; Jia Li, 24633366@qq.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.